Algo +5.34% on B-SUPREME Study Progress and Leadership Changes

Algos (ALGO) climbed 5.34% within 24 hours on January 21, 2026, reaching $0.1194, despite a 7.6% drop over the previous week. The upward movement followed key developments in Aligos Therapeutics’ Phase 2 B-SUPREME clinical trial for pevifoscorvir sodium, its investigational treatment for chronic hepatitis B virus (HBV).

B-SUPREME Study Reaches Enrollment Milestones

Aligos Therapeutics, the publicly traded biopharmaceutical company behind ALGO, announced that 144 participants are currently enrolled in the Phase 2 B-SUPREME study of pevifoscorvir sodium. The trial, which is evaluating the drug’s safety and efficacy in adults with chronic HBV, is progressing on schedule.

Two planned interim analyses are set for 2026. The first is expected in the first half of the year and will review data from approximately 36 HBeAg-negative participants who completed 12 weeks of treatment. The second interim analysis, slated for the second half of the year, will evaluate approximately 55 HBeAg-positive participants who have completed 24 weeks of treatment.

To maintain data integrity and comply with FDA requirements, the company will remain blinded to subject-level data and will receive insights from the Data Safety Monitoring Board.

Leadership Transition

In a separate update, Aligos announced that Hardean Achneck, MD, has resigned from his role as Executive Vice President and Chief Medical Officer. The company has launched a search for his successor, signaling a strategic shift as it advances its HBV pipeline.

Strategic Direction and Clinical Focus

Pevifoscorvir sodium is being developed as a first-in-class oral capsid assembly modulator for chronic HBV. The drug has already demonstrated sustained reductions in HBV markers in earlier Phase 1 trials and has been well-tolerated. The B-SUPREME study, a randomized, double-blind, active-controlled trial, is comparing pevifoscorvir sodium monotherapy to tenofovir disoproxil fumarate in approximately 200 untreated adults over 48 weeks.

Topline data is expected in 2027, with the company expressing confidence in the study’s progress.

Recent Leadership and Commercial Strategy

Earlier in January, Aligos announced the appointment of James Hassard as Executive Vice President and Chief Commercial Officer. The hiring reflects the company’s focus on preparing for commercialization as it moves closer to potential regulatory milestones.

Market Context

While Algos has seen short-term volatility, including a 7.6% decline over the past week, its longer-term performance has been more resilient, with gains of 8.96% in both the past 30 days and the past year. The stock remains underpinned by its clinical-stage pipeline and strategic hires in key leadership roles.

Analysts project that successful interim analyses and enrollment completion could serve as catalysts for further investor interest, especially as the company prepares for data readouts in 2027.